Lyell Immunopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Lyell Immunopharma, Inc. on May 28, 2025, covering events occurring on May 27, 2025. The filing details a material modification to the rights of security holders involving a reverse stock split of the company's common stock.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on capital structure adjustments.
Material Changes
- Reverse Stock Split: The Company implemented a 1-for-20 reverse stock split, authorized by stockholders on May 15, 2025.
- Effective Date: The split became effective at 5:00 p.m. Eastern Time on May 30, 2025.
- Share Count Adjustment: As of May 27, 2025, there were 296,161,570 shares outstanding. Post-split, the count is approximately 14,808,078 shares (subject to fractional share cash-outs).
- Trading Details: Trading on the Nasdaq Global Select Market resumed on a split-adjusted basis on June 2, 2025, under the new CUSIP number 55083R203.
- Equity Plan Adjustments: Stock options and restricted stock units were adjusted proportionately (decreased share count, increased exercise price). The number of shares reserved under the 2021 Equity Incentive Plan and 2021 Employee Stock Purchase Plan was reduced proportionately.
- Fractional Shares: No fractional shares were issued; holders entitled to fractions received cash payments in lieu thereof.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future financial guidance, operational outlook, or specific risk factors beyond the mechanics of the stock split. The primary purpose is to notify the market of the change in share structure and trading parameters.
Investor Verification Checklist
- Verify the new CUSIP number (55083R203) for trading purposes starting June 2, 2025.
- Confirm the adjusted number of shares held and any cash payments received for fractional shares.
- Review the updated exercise prices and share quantities for any outstanding stock options or restricted stock units.
- Check the updated share count of approximately 14.8 million shares for dilution and ownership percentage calculations.